Elsevier

Joint Bone Spine

Volume 72, Issue 4, July 2005, Pages 330-334
Joint Bone Spine

Case report
Severe pyogenic infections in patients taking infliximab: A regional cohort study

https://doi.org/10.1016/j.jbspin.2004.09.003Get rights and content

Abstract

Objective. – To evaluate the prevalence and risk factors of severe pyogenic infections in rheumatology patients taking infliximab in everyday practice.

Methods. – Regional prospective cohort study of patients taking infliximab for rheumatoid arthritis or ankylosing spondylitis with data collection on standardized forms. The medical records of patients with severe pyogenic infections were subjected to a detailed retrospective review. Patients with and without severe pyogenic infections were compared.

Results. – The cohort included 83 patients (55 women and 28 men). Severe pyogenic infections occurred in five (6%) patients (three women and two men), all of whom had acute or underlying risk factors. Higher values were found in these five patients for mean age (65.8 ± 12 vs. 53.9 ± 13 years, P = 0.04) and mean daily glucocorticoid dosage (15.5 ± 9 vs. 6.9 ± 7 mg/day prednisone-equivalent, P = 0.036), as compared to the other patients.

Conclusion. – Older age and high-dose glucocorticoid therapy are associated with an increased risk of severe pyogenic infection during infliximab therapy. Caution is in order when starting and monitoring infliximab therapy in patients with risk factors. Our data also emphasize the need for a careful search for risk factors before each infliximab infusion.

Introduction

Infliximab has considerably benefited the management of patients with rheumatoid arthritis (RA) [1], [2], [3] and, more recently, with ankylosing spondylitis (AS) [4], [5], [6], [7]. Despite a good safety profile [8], [9], infliximab can induce side effects, which include infections [10], [11]. Published data have alerted clinicians to the risk of opportunistic infections and mycobacterial infections [12], [13]. Patient selection strategies designed to prevent these infections have been suggested [14].

Pyogenic infections have been reported also [15], [16], [17], [18]. Although minor in most instances, pyogenic infections can be life-threatening. There is no proof that the risk of severe pyogenic infections is increased by infliximab therapy. Neither is there any firm evidence that pyogenic infections in patients taking infliximab therapy are more severe or occur in association with specific patient-related factors. This probably explains why the preventive strategies suggested to date (e.g., pneumococcus immunization [19]) are less well standardized than those for tuberculosis. Thus, the recently published conclusions of a consensus conference merely indicate that infliximab therapy should not be started, or should be discontinued, in patients with severe infections such as septic arthritis, osteomyelitis, acute abscesses, infection of a prosthesis, sepsis, etc. [20]. According to the Summary of Product Characteristics, infliximab is “contraindicated in patients with severe infection such as sepsis, abscesses, tuberculosis, and opportunistic infections” and “should be discontinued if severe infection or sepsis develops”. The recommendations issued by the British Society for Rheumatology are somewhat more detailed [21], as they list among the contraindications to infliximab therapy the presence of risk factors for infection, such as chronic leg ulcer, a history within the last year of septic arthritis or infection of a prosthesis, a history of infection of a prosthesis at any time without removal of the implant, and a history of recurrent or relapsing lower respiratory tract infections.

Thus, large gaps exist in the currently available data on severe pyogenic infections in patients taking infliximab. In particular, little is known about risk factors. Recommendations for preventing these infections are often vague. The media have given less attention to pyogenic infections than to tuberculosis. Thus, when evaluating the risk/benefit ratio of infliximab therapy in potential candidates for this drug, clinicians may give greater weight to tuberculosis than to pyogenic infections.

Shortly, after infliximab was introduced on the market in France, a hospital network (the Bourgogne Infliximab Network) was set up in the Bourgogne region with the objective of collecting standardized follow-up data on all patients taking infliximab. Although risk factors for pyogenic infections are not listed on the data collection form, the available information may help to clarify the potential link between infliximab therapy and severe pyogenic infections. Indeed, the network has many strong points: multiple centers in the Bourgogne region include all patients given infliximab for RA or AS, data collection is highly standardized, and the patients are studied under the conditions of everyday clinical practice. Consequently, we evaluated the prevalence of severe pyogenic infections in the cohort and sought to identify risk factors.

Section snippets

Methods

All patients given infliximab for RA or AS in centers participating in the Bourgogne Infliximab Network were included prospectively in the cohort. The network includes all nine hospital departments in Bourgogne where one or more rheumatologists work either full time or part time (Auxerre, Avallon, Chalon sur Sâone, Dijon, Le Creusot, Mâcon, Montceau les Mines, Nevers, and Sens). The main objective of the network is to standardize the management and follow up of RA and AS patients given

Results

Eight of the nine centers in the Bourgogne Infliximab Network accepted to participate in the study. During the study period, 83 patients (55 women and 28 men with a mean age of 53.9 ± 13 years) were given infliximab to treat RA (60 patients including 48 women and 12 men with a mean age of 57.2 ± 13 years) or AS (23 patients including eight women and 15 men with a mean age of 45.5 ± 10 years). The mean oral glucocorticoid dosage at infliximab initiation was 9.3 ± 7 mg prednisone-equivalent in RA

Discussion

The prevalence of severe pyogenic infections was 6% in our cohort of patients given infliximab therapy for chronic inflammatory joint disease. At least one risk factor was present in every case.

Although some of our study data were collected prospectively, others were obtained by retrospective medical record review. This is the main weakness of our study. Because the retrospectively collected variables were not available for the entire cohort, we were unable to compare them in the groups with

Acknowledgments

We are grateful to the other physicians participating in the Bourgogne Infliximab Network: C. Bressot, A. Cherasse, J.A. Dellas, J. Dupuis, M. Falconnet, L. Julien, F. Marchand, N. Richard, and C. Sidot.

References (28)

  • T.I. Temekonidis et al.

    Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study

    Ann. Rheum. Dis.

    (2003)
  • T.F. Schaible

    Traitement de maladies inflammatoires : sécurité d’emploi à long terme de l’infliximab

    Press. Med.

    (2001)
  • W.J. Shergy et al.

    Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

    J. Rheumatol.

    (2002)
  • M.H. Weisman

    What are the risks of biologic therapy in rheumatoid arthritis? An update on safety

    J. Rheumatol.

    (2002)
  • Cited by (19)

    • Pyogenic spondylodiscitis following anti-interleukin-6 therapy in a patient with rheumatoid arthritis (implication of hematogenous infection risk in degenerative intervertebral discs): A case report and review of the literature

      2016, Journal of Orthopaedic Science
      Citation Excerpt :

      Results from the Dutch RA monitoring registry showed that the incidence rate of a first serious infection in patients with RA receiving tumor necrosis factor-inhibiting therapy was approximately 1–4 per 100 patient-years and that 10.4% of the serious infections were musculoskeletal [1]. A French prospective cohort study of patients taking infliximab for RA or ankylosing spondylitis showed that severe pyogenic infections occurred in 5 of 83 patients (6%) and 1 of the 5 developed spondylodiscitis [2]. Therefore, pyogenic spondylodiscitis should be suspected in patients with RA receiving biologic therapy when they complain of neck or back pain.

    • The risk of infections with biologic therapies for rheumatoid arthritis

      2010, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      Two of these patients died; 1 from bacterial pneumonia and the other from bacterial meningitis. Five cases (6% of patients) of severe pyogenic infection were reported in a French study of 83 patients treated with infliximab (32). A short-term open-label retrospective study involving 88 patients treated with infliximab plus leflunomide (mean number of infliximab infusions: 4.8) reported 10 infections (5 viral and 5 bacterial), 1 death (from bacterial pneumonia), but no cases of tuberculosis or opportunistic infections (33).

    View all citing articles on Scopus
    View full text